Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not yet recruiting

Safety and effectiveness study of PN6047 HCl in adults with peripheral neuropathic pain and mechanical allodynia

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This study focuses on people with peripheral neuropathic pain who experience mechanical allodynia, a condition where normal touch causes pain. The research evaluates a new medication called PN6047 HCl, which is taken as a capsule by mouth. The study tests this medication against a placebo to determine if it is safe and effective for treating this type of nerve pain.

The study uses a design where participants receive both the study medication and placebo at different times during the trial. Each person will take either PN6047 HCl capsules or matching placebo capsules for a specified period, and then switch to the other treatment. The maximum daily dose of the study medication is 300 mg, and treatment can last up to 20 days.

Throughout the study, participants will need to rate their pain levels and report how touch affects their pain. The research team will monitor the safety of the treatment by performing various health checks, including blood tests and heart measurements. Participants will also be asked about any changes in their daily activities, sleep, and mood while taking the study medication.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial trial period

    You will start by taking either PN6047 HCl capsules or placebo capsules (inactive substance) orally.

    The trial follows a cross-over design, which means you will receive both treatments at different times.

    You will need to maintain a pain diary where you will rate your pain twice daily using a scale from 0 to 10.

  2. Step 2

    Pain assessments

    Your pain will be evaluated in several ways:

    Rating your average pain over the last 12 hours

    Recording touch-related pain in the painful skin area

    Evaluating how pain affects your sleep, daily activities, and mood

    Completing a Neuropathic Pain Symptom Inventory

    Rating your pain relief experience

  3. Step 3

    Blood sampling

    Blood samples will be collected on days 7, 20, 35, and 48:

    Samples taken before medication and at 30, 60, 90 minutes, and 4 hours after dose

    On day 29, only one sample before taking medication will be collected

  4. Step 4

    Safety monitoring

    Throughout the trial, several safety checks will be performed:

    Laboratory tests to monitor your health

    Vital signs measurements

    Physical examinations including neurological checks

    Electrocardiogram (ECG) to monitor heart activity

    Any side effects will be recorded and evaluated

  5. Step 5

    Rescue medication

    Paracetamol will be available as rescue medication if needed

    The amount of rescue medication used will be monitored and recorded

Who can join the trial?

14 criteria

  • You must provide informed consent before any trial procedures begin
  • You must be able to swallow a size 0 capsule
  • You must be between 18 and 70 years old
  • Your Body Mass Index (BMI) must be between 18.5 and 35.0
  • You must have been diagnosed with neuropathic pain (nerve pain) that is either "probable" or "definite"
  • Your nerve pain must have lasted for at least 3 months
  • Your pain must be caused by one of these conditions: - Diabetic neuropathy (nerve damage from diabetes) - Post-herpetic neuralgia (pain after shingles) - Nerve injury from trauma, compression, or surgery
  • Your usual pain level must be between 4 and 9 on a 0-10 scale
  • You must have pain when touched (mechanical allodynia) with intensity between 4 and 9 on a 0-10 scale
  • Women who can become pregnant must use highly effective birth control methods during the study and for 30 days after
  • Men must either use condoms, practice abstinence, or have had a vasectomy during the study and for 30 days after
  • You must not donate eggs (women) or sperm (men) during the study and for 3 months after
  • You must be willing to stop taking certain medications at least 5 days before the study begins
  • You must be able to follow all study requirements as determined by the study doctor

Who cannot join the trial?

15 criteria

  • Age below 18 years or above 65 years
  • Pregnant or breastfeeding women
  • History of chronic pain conditions other than peripheral neuropathic pain
  • Current use of strong pain medications (such as opioids)
  • Significant medical conditions affecting the nervous system
  • History of substance abuse or addiction
  • Severe kidney or liver problems
  • Participation in other clinical trials within the past 30 days
  • Known allergies to the study medication or similar compounds
  • Uncontrolled high blood pressure or heart conditions
  • Mental health conditions that could interfere with pain assessment
  • Use of certain medications that might interact with the study drug
  • Inability to follow study procedures or attend scheduled visits
  • History of seizures or epilepsy
  • Severe skin conditions in areas where pain measurements will be taken
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

PN6047 HCl is an investigational medication being studied for treating peripheral neuropathic pain. This medication is specifically being tested in people who experience pain when their skin is touched lightly, a condition known as mechanical allodynia. The medication is being evaluated to determine if it is safe for patients to use and how well patients can tolerate it.

What is already known about the treatment

PN6047 HCl – An investigational drug being studied in clinical trials for the treatment of peripheral neuropathic pain characterized by mechanical allodynia, a condition where normal touch causes pain sensations. This medication is administered in a controlled clinical setting under double-blind, placebo-controlled conditions to evaluate its safety and tolerability in patients. While the exact molecular mechanism is still under investigation in clinical trials, the compound is being developed specifically to target the underlying mechanisms of neuropathic pain and mechanical allodynia. The drug represents a potential new therapeutic option in the field of pain management, though it is currently only available within authorized clinical trial settings and not yet approved for general medical use.

Investigated diseases

  • Mechanical allodynia

    A neurological condition where normal, light touch or pressure triggers pain sensations that wouldn't typically be painful. It occurs when the nervous system becomes oversensitive, causing non-painful stimuli like clothing touching the skin or light pressure to produce pain. The condition commonly develops as part of peripheral neuropathic pain, where nerve damage or dysfunction leads to abnormal pain processing. Normal activities like wearing clothes, being touched, or exposure to mild temperature changes can trigger pain responses. The affected areas of skin become extremely sensitive, and even gentle contact can cause significant discomfort.

  • Peripheral neuropathic pain

    A type of chronic pain caused by damage or disease affecting the peripheral nervous system. The condition results from injury or malfunction of the nerves that carry signals between the central nervous system and the rest of the body. It typically causes burning, tingling, or shooting pain sensations in affected areas. The pain can be constant or occur intermittently, and may be accompanied by numbness or increased sensitivity to touch.

Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-517304-12-00Estimated enrolment65 patientsSponsorPharmnovo AB

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.